TCBP Provides Update on Acquisition Strategy and Current Targets

Provided By PR Newswire

Last update: Dec 31, 2024

EDINBURGH, Scotland, Dec. 31, 2024 /PRNewswire/ -- TC BioPharm (Holdings) PLC ("TC BioPharm" or the "Company") (NASDAQ: TCBP) a clinical-stage biotechnology company developing platform allogeneic gamma-delta T-cell therapies for cancer and other indications, today announced it has advanced negotiations with both of its previously aforementioned acquisition candidates.